Morphine is commonly used in neonates with hypothermic ischemic encephalopathy (HIE) during therapeutic hypothermia to provide comfort and analgesia. However, pharmacokinetic data to support morphine dosing in this vulnerable population are lacking. A prospective, 2-center clinical pharmacokinetic study of morphine was conducted in 20 neonates (birthweight, 1.82-5.3 kg) with HIE receiving hypothermia. Morphine dosing was per standard of care at each center. Morphine and glucuronide metabolites (morphine-3-glucuronide and morphine-6-gluronide) were measured via a validated dried blood spot liquid chromatography-tandem mass spectrometry assay. From the available concentration data (n = 106 for morphine; n = 106 for each metabolite), a population pharmacokinetic model was developed using nonlinear mixed-effects modeling. The clearance of morphine and glucuronide metabolites was best predicted by birthweight allometrically scaled using an exponent of 1.23. In addition, the clearance of each glucuronide metabolite was influenced by serum creatinine. No other significant predictors of clearance or volume of distribution were found. For a 3.5-kg neonate, morphine clearance was 0.77 L/h (CV, 48%), and the steady-state volume of distribution was 8.0 L (CV, 49%). Compared with previous studies in full-term newborns without HIE, morphine clearance was markedly lower. Dosing strategies customized for this vulnerable population will be needed. Applying the final population pharmacokinetic model, repeated Monte Carlo simulations (n = 1000 per simulation) were performed to evaluate various morphine dosing strategies that optimized achievement of morphine concentrations between 10 and 40 ng/mL. An optimized morphine loading dose of 50 μg/kg followed by a continuous infusion of 5 μg/kg/h was predicted across birthweights.
Current understanding of the dose needs of commonly used drugs in neonates with hypoxic ischemic encephalopathy (HIE) receiving hypothermia therapy is limited. Alterations in drug pharmacokinetics are expected because of frequent associated hypoxic-ischemic injury to organs important in drug elimination (ie, liver and kidney) [1] [2] [3] [4] [5] and potential changes in organ physiology and blood flow during hypothermia. 6 Therefore, it is critical to consider the unique clinical pharmacologic needs of this vulnerable population. For example, a recent clinical study examined the pharmacokinetics of gentamicin in neonates with HIE receiving hypothermia that demonstrated a marked reduction in gentamicin clearance and the need for extended dosing intervals. 7, 8 Careful inquiry into the pharmacokinetics of other drugs used in the HIE population can help to further advance customized evidenced-based dose recommendations. 9 Morphine is commonly used in neonates with HIE to provide comfort and analgesia during therapeutic hypothermia and/or assisted ventilation. Morphine is metabolized in the liver by UDP glucuronosyltransferase 2B7 (UGT2B7) to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). 10 Delayed maturation of UGT2B7 in the neonate results in enzymatic activity <10% of adults and subsequent decreased morphine clearance and metabolite formation. 11 After formation, the metabolites are subsequently eliminated via the kidney, and kidney maturation and function influence metabolite pharmacokinetics. 12 In addition, M6G is an active metabolite and contributes to analgesia and sedation. 10 Understanding the pharmacokinetics of both morphine and its metabolites will therefore be necessary to develop a therapeutic framework for morphine in neonates with HIE receiving hypothermia.
Current pharmacokinetic data to support morphine dosing in neonates with HIE receiving hypothermia are limited. A small clinical study demonstrated neonates with HIE receiving hypothermia and standard morphine infusion rates frequently (n = 6/7) had elevated morphine concentrations >300 ng/mL, 13 which are exposures associated with toxicity in neonates including respiratory depression.
14 Morphine metabolites were not measured. Because of study design limitations of this secondary analysis, a quantitative pharmacokinetic framework was not established, and no alternative dosing strategies were recommended. Nonetheless, this study clearly demonstrates the need for further inquiry. The objective of the current prospective clinical pharmacokinetic study was to evaluate the pharmacokinetics of morphine in neonates with HIE receiving hypothermia and use the information gained to develop a customized morphine dosing strategy in this population.
Methods

Study Design
The Stanford University Institutional Review Board and University of California San Francisco (UCSF) Committee on Human Research approved the study. This was a prospective, open-label clinical pharmacokinetic study of morphine in 20 neonates with HIE receiving hypothermia. It was conducted at 2 centers: UCSF Benioff Children's Hospital and Lucile Packard Children's Hospital at Stanford University (LPCH). Both centers are academic level III neonatal intensive care units with expertise in caring for neonates with HIE including therapeutic hypothermia. Informed parental consent was obtained for each patient.
Patients
Neonates with moderate to severe HIE treated with whole-body therapeutic hypothermia (33.5°C) and receiving morphine as part of the standard of care were eligible for enrollment. Patients at each center meeting inclusion and exclusion criteria were enrolled consecutively. Eligibility criteria for hypothermia were based on the CoolCap 2 (at UCSF) or National Institute of Child Health and Human Development (at LPCH) studies. 15 Additional study exclusion criteria included known major structural or chromosomal abnormality, requirement of continuous renal replacement therapy, peritoneal or hemodialysis, requirement of extracorporeal membrane oxygenation, or decision made to withhold full support.
Morphine Administration
Morphine was administered intravenously as morphine sulfate at both centers. The decision to prescribe morphine and the dosing regimen were per the treating clinical team. At the time of study, the recommended starting morphine dose at UCSF was 20 μg/kg/h via continuous intravenous infusion, with a planned dose reduction to 10 μg/kg/h 24 hours after the onset of hypothermia treatment. The recommended starting morphine dose at LPCH for neonates with HIE receiving hypothermia was 40 μg/kg every 6 hours given over 10 minutes. This dose was lower than the standard morphine dose of 50-100 μg/kg every 4 hours used in full-term neonates without HIE at LPCH and was reduced based on the concern for elevated morphine concentrations at standard doses in neonates with HIE receiving hypothermia. 13 At LPCH, morphine could alternatively be given as a continuous intravenous infusion of 10 to 20 μg/kg/h. At both centers, the dose was adjusted based on assessment of clinical need (ie, pain, discomfort, and shivering), as determined by the treating clinical team. Additional intermittent bolus doses of morphine (50-100 μg/kg) were given as needed for pain, discomfort, and shivering.
Pharmacokinetic Sampling
Dried blood spot (DBS) samples for pharmacokinetic analysis were collected during hypothermia. Samples were collected during 2 different periods for each patient while receiving morphine. Period first was between 12 and 48 hours after the start of hypothermia, and period 2 was between 48 and 72 hours after the start of hypothermia. Flexibility in the timing of pharmacokinetic samples was allowed. For patients receiving a continuous infusion, 2 DBS samples at least 4 hours apart were collected during period first and period 2 (ie, total of 4 DBS samples). For patients receiving intermittent dosing, DBS samples were collected at the following times relative to a morphine dose: period first (predose), 0.25-0.75, 1-2, 3-4, and 5-6 hours, and period 2, 0.25-3 and 4-6 hours. Samples were collected around the same dose for a given period.
For each DBS sample, ß100 μL of whole blood was collected on Whatman 903 filter paper cards (ß50 μL whole blood/spot × 2 spots) from an indwelling catheter already in place for clinical care. After allowing to airdry for 4-24 hours, the DBS sample was then stored at less than −80°C until analysis. The concentrations of morphine, M3G, and M6G in whole blood were measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) DBS assay by iC42 (Denver, Colorado). 16 The lower limit of quantification was 1 ng/mL for morphine and 5 ng/mL for M3G and M6G. The calibration curves were linear from 1 to 1000 ng/mL for morphine and 5 to 1000 ng/mL for M3G and M6G. The within-run and betweenrun coefficients of variation were ࣘ11% for morphine, ࣘ11% for M3G, and ࣘ15% for M6G. The median duration of time DBS samples were stored at −80°C prior to LC-MS/MS analysis was 5.5 months (range, 2.3-8.2 months). A previous study has shown morphine to be stable in DBS for at least 6 months at −20°C.
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Population Pharmacokinetic Analysis A population pharmacokinetic model was developed from the morphine, M3G, and M6G concentrationtime data using the nonlinear mixed-effects modeling program (NONMEM; version VII, Icon Development Solutions). The first-order conditional estimation method with interaction was used throughout the model building and evaluation process. Morphine and both metabolites were simultaneously fitted. The dose of morphine sulfate in μg was converted to morphine in micrograms according to morphine dose = F MW × morphine sulfate dose , where F MW is the fractional difference in molecular mass between morphine and morphine sulfate equal to 0.853. Similarly, concentrations of M3G and M6G were converted to nanograms of morphine units per milliliter using an F MW of 0.618.
The pharmacokinetic structural model implemented is shown in Figure 1 . For morphine, both 1-and 2-compartment models with first-order elimination were examined, parameterized in terms of total clearance (CL MORPHINE ), intercompartmental clearance (Q), and central (V 1 ) and peripheral (V 2 ) volume of distribution. Formation clearances of M3G and M6G were represented as fractions (FMET3 and FMET6) of morphine total clearance. FMET3 and FMET6 were estimated in the model. Morphine elimination by other routes was calculated as CL O = CL MORPHINE × (1 − FMET3 − FMET6). The pharmacokinetics of the metabolites were described by a 1-compartment model parameterized in terms of elimination clearance (CL M3G and CL M6G ) and distribution volume (V M3G and V M6G ). V M3G and V M6G could not be identified with the present study design and were fixed to 1.2 L and 1.5 L, respectively, based on values reported in the adult literature after scaling linearly for weight. 18, 19 Interindividual variability in pharmacokinetic parameters was evaluated using an exponential error model. To model the residual (or intraindividual) variability, a proportional error model was implemented. Selection between structural models was based on the difference in the NONMEM objective function value (OFV) and visual comparison of standard diagnostic plots. The difference in OFV between 2 models has an approximate χ 2 distribution, with degrees of freedom equal to the difference in the number of parameters between models. Significance was set at a decrease in OFV larger than 10.83, corresponding to a P <.001.
Once the structural pharmacokinetic model was established, the covariate model was developed. Based on previous population pharmacokinetic models for a range of compounds in neonates and children, an allometric model of birthweight was first implemented to account for the influence of body size on elimination clearance (CL MORPHINE , CL M3G , and CL M6G ) and volume of distribution (V 1 and V 2 ). 20 The exponent defining the relationship of birthweight and clearance was examined both as a fixed (0.75) and an estimated (k) parameter. The exponent defining the relationship of birthweight and volume was fixed to 1. Next, the potential effect for maturational changes of UGT2B7 in neonates was explored using gestational age (GA) as a predictor of CL MORPHINE applying a sigmoid E max maturation function. Because of the relatively limited range of GA in the study population (interquartile range, 37.2 to 40.4 weeks), the sigmoid E max maturation function was not identifiable. Therefore, parameters were fixed to those reported by Holford et al (maturation half-life, 58.1 weeks; slope parameter for the sigmoid Emax model, −3.58).
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Additional biologically and/or clinically plausible covariates were also evaluated for their influence on pharmacokinetic parameters. Continuous covariates investigated included postnatal age, serum creatinine (SCr), and urine output. Biomarkers of severity of hypoxic-ischemic injury at birth were also evaluated (eg, lowest blood pH, highest blood base deficit, APGAR score at 5 minutes). Categorical covariates evaluated included concomitant medications (dopamine, lorazepam, gentamicin, phenobarbital), "severe" HIE diagnosis (based on the modified Sarnat classification scale 22 ), diagnosis of pulmonary hypertension, need for assisted ventilation, and alanine aminotransferase ࣙ100 U/L. The effect of a continuous covariate on a parameter was modeled using a power function. Continuous covariates were scaled to their median values. Categorical covariates were modeled proportionally, that is, the fractional change in clearance when the categorical covariate was true.
The covariate model was built using a standard forward addition, backward deletion procedure. Covariates were added in a stepwise manner to the model in the order of their reduction in the OFV. During forward stepwise addition, a covariate was allowed to enter the model as long as the decrease in OFV because of its addition was larger than 3.84, corresponding to a P <.05. After the stepwise addition terminated, the model was pruned using backward elimination. Covariates were eliminated one at a time until the removal of a covariate resulted in an OFV increase of more than 10.83, corresponding to a P <.001. To evaluate the accuracy and stability of the final pharmacokinetic model, a nonparametric bootstrap resampling method was performed using the NON-MEM support software Perl-speaks-NONMEM (PsN, version 3.6.2). A total of 1000 bootstrap data sets were generated from the original data set by repeated sampling with replacement, and the final pharmacokinetic model was used to estimate model parameters for each data set. In addition, the final pharmacokinetic model was assessed using an internal evaluation procedure by computing the normalized prediction distribution errors (NPDE) of 5000 simulated data sets compared with the observed data set. 23, 24 Dose-Exposure Relationships Simulations were conducted to evaluate morphine sulfate dosing regimens in neonates with HIE receiving hypothermia. Using the final population pharmacokinetic model parameter estimates, the pharmacokinetic profiles of 1000 neonates were repeatedly simulated. Morphine sulfate doses given as a continuous intravenous infusion (range, 2.5 to 20 μg/kg/h) and intermittent dose (range, 20 to 100 μg/kg) every 6 hours were examined. Birthweights evaluated ranged from 2.5 to 4.5 kg. The predicted morphine, M3G, and M6G concentrations at steady state were examined for each simulation. Although morphine concentrations needed in neonates for analgesia are not firmly established (and may vary by patient depending on age, disease, concomitant medications, pain sources, etc.), effective concentrations in the range of 10-40 ng/mL have been reported. [25] [26] [27] [28] Therefore, "optimized" morphine sulfate doses were selected that maximized achievement of morphine concentrations between 10 and 40 ng/mL across simulated neonates. In addition, a sensitivity analysis was conducted to evaluate the influence of serum creatinine on metabolite concentrations. Simulations were conducted as described above; however, the dose was held constant while the serum creatinine was varied from 0.4 to 1.6 mg/dL between simulations.
Results
Patients and Morphine Concentrations
Twenty neonates (LPCH, n = 13; UCSF, n = 7) with HIE treated with hypothermia were enrolled and had morphine data available for analysis. Patient characteristics are shown in Table 1 . Morphine was given as intermittent dosing in 10 neonates and continuous infusion in 10 neonates. The median (range) intermittent dose was 40 μg/kg (40-60 μg/kg) every 6 hours during period 1. No dose changes were made between period first and period 2. The median (range) continuous infusion was 15 μg/kg/h (10-20 μg/kg/h) during period first and 10 μg/kg/h (10-20 μg/kg/h) during period 2.
All patients completed pharmacokinetic sampling as scheduled except 1 neonate, who had pharmacokinetic sampling only during period first (intermittent dosing 
IQR, interquartile range; Cr max , maximum serum creatinine during hypothermia; ALT max , maximum alanine aminotransferase during hypothermia; temperature core, esophageal temperature at time of pharmacokinetic sampling.
schedule) because of redirection of the goals of care and early discontinuation of therapeutic hypothermia. No morphine, M3G, or M6G concentrations were below the limit of quantification. Two DBS samples from 1 patient were considered outliers (morphine concentrations of 1560 and 454 ng/mL) and were not included in the analysis. All other morphine concentrations for this patient were <31 ng/mL. Therefore, a total of 106 concentrations were available each for morphine, M3G, and M6G.
Population Pharmacokinetic Analysis
The time course of morphine whole-blood concentrations was best described by a 2-compartment model with first-order elimination and an exponential error model for interindividual variability on morphine clearance (CL MORPHINE ) and central volume (V 1 ). The peripheral volume of morphine (V 2 ) was not found to be significantly different than V 1 . Therefore, V 2 was fixed to equal V 1 , which improved the precision of model parameter estimates and reduced interindividual variability.
The whole-blood concentrations of the M3G and M6G metabolites were each adequately described in terms of formation clearance represented as a fraction (FMET3 and FMET6, respectively) of total morphine clearance followed by first-order elimination from a 1-compartment model. Interindividual variability in the elimination clearance of M3G (CL M3G ) and M6G (CL M6G ) were not found to be significantly different, and a single exponential error model was used to describe the interindividual variability for both metabolite clearances. This is congruent with both metabolites having the same route of elimination (ie, renal). After accounting for the fraction of morphine metabolized to M3G and M6G, morphine clearance by other routes (Cl O ) accounted for 62% of morphine clearance. The residual (or intraindividual) variability was best described by a proportional error model with different errors for morphine, M3G, and M6G.
Once the structural model was established, the covariate model was developed. Birthweight was highly predictive of CL MORPHINE , CL M3G , and CL M6G (OFV, −15; P <.001). The exponent (k wt ) defining the allometric relationship of birthweight and clearance was estimated to be 1.23. Fixing k wt = 0.75 resulted in a 2.7 increase in objective function. Given a previous report that found k wt = 1.44 for morphine pharmacokinetics in neonates, k was allowed to be estimated in the final model. 12 Estimating different values of k wt for CL MORPHINE , CL M3G , and CL M6G did not improve the model. No significant relationship between birthweight and volume was identified (OFV, +2.2; P >.05), and therefore birthweight as a covariate on volume was not included in the final model.
After incorporating the allometric model of weight on morphine and metabolite clearances, serum creatinine was identified as a significant predictor of M3G and M6G clearance (OFV, −52; P <.001). In addition, GA (OFV, −4.7; P <.05) and dopamine (OFV, −6.4; P <.05) were found to significantly impact morphine clearance during forward stepwise addition. However, during backward elimination, neither met the statistical criterion of P <.001 for remaining in the final model, and both were removed. No other significant covariates were identified. Of note, a model implementing both a fixed allometric weight exponent of 0.75 and GA on clearance was not significantly better compared with our final model having only an estimated allometric weight exponent (OFV, −2.6; P >.05).
The final population pharmacokinetic model parameter estimates are presented in Table 2 . In general, observed versus population and individual predicted concentrations showed no systemic bias (Figure 2) , and the weighted residuals were homogeneously scattered for both parent and metabolites (data not shown). The parameter estimates as found by bootstrap were in agreement with those obtained by the final population pharmacokinetic model (Table 2) 
NPDE is zero with a variance pf 1.0. The percentage of observations that fell inside the theoretical 90% prediction interval was 92%, 91%, and 90% for morphine, M3G, and M6G, respectively. In addition, there were no major trends in NPDE across time, birthweight, or GA ( Figure 3 ).
Dose-Exposure Relationships
Morphine exposure after various morphine sulfate dosing regimens in neonates with HIE receiving hypothermia was simulated using the final pharmacokinetic model and Monte Carlo methods. A continuous morphine infusion of 5 μg/kg/h was predicted to maximize achievement of target morphine concentrations of 10-40 ng/mL (Figure 4) . At a continuous morphine infusion of 5 μg/kg/h, 81% of simulated neonates weighing 3.5 kg achieved a concentration within the target morphine concentration range. At a morphine infusion of 10 μg/kg/h, a dose that is routinely used for analgesia and sedation in full-term neonates without HIE, only 54% of neonates with HIE receiving hypothermia achieved a concentration within the target range, and 46% had a morphine concentration >40 ng/mL.
Overall, variability in morphine exposure was high between neonates, with >4-fold variation in concentrations at a given dose and weight. For example, the 90% range of morphine steady-state concentrations in simulated neonates was 9.6 to 37.4 ng/mL at an infusion of 5 μg/kg/h and birthweight of 3.5 kg. The impact of birthweight on the achieved morphine concentration for a given dose in micrograms per kilogram was small and likely not clinically relevant in terms of starting dose selection (Figure 4 ). Similar trends were seen for intermittent every-6-hour dosing. An intermittent dose of 40 to 50 μg/kg every 6 hours was predicted to maximize achievement of target trough morphine concentrations (Supplemental Figure S1) .
Based on the final model, metabolite concentrations were impacted by serum creatinine. M6G clearance was reduced by approximately 30% (from 0.26 to 0.18 L/h), whereas serum creatinine increased from 0.6 to 1.2 mg/mL for a 3.5-kg neonate. Figure 5A shows the time course of the active metabolite M6G at different serum creatinine levels in a median neonate weighing 3.5 kg after a 50 μg/kg loading dose followed by a continuous morphine infusion of 5 μg/kg/h. As serum creatinine increased, higher M6G concentrations were predicted. In addition, metabolite concentrations continued to accumulate over the first 12-24 hours of dosing, which may be clinically relevant given that M6G is an active metabolite, resulting in an increased effect over time despite a stable dose. A similar trend was seen for the metabolite M3G ( Figure 5B ).
Discussion
This is the first study to describe the population pharmacokinetics of morphine and its glucuronide metabolites in neonates with HIE receiving hypothermia. Similar to previous morphine population pharmacokinetic models in neonates without HIE and young children, morphine pharmacokinetics were adequately described by a 2-compartment model for morphine and 1-compartment model for each of the metabolites. 12, 29, 30 The major study finding was that morphine clearance was markedly lower in neonates with HIE receiving hypothermia compared with reports in full-term normothermic neonates <7 days old without HIE. 12, 21, 30 Accordingly, lower morphine doses will be needed in this vulnerable population of neonates to achieve exposures suggested for analgesia in neonates and children without hypothermia.
Understanding the unique drug dose needs of neonates with HIE receiving hypothermia will be essential to continuing the advancement of their clinical care. 6 Extrapolation of general pharmacologic understanding from nonasphyxiated, normothermic neonates can be a useful starting point. For example, the pharmacokinetics of morphine in neonates is already known to be highly variable, 12, 21, 30 and therefore, variation in morphine pharmacokinetics in neonates with HIE receiving hypothermia is expected. In addition, kidney function is known to impact elimination of the active M6G metabolite. 29, 31, 32 However, neonates with HIE receiving hypothermia represent a distinct and vulnerable population from a pharmacologic perspective, and extrapolation of dose strategies from nonasphyxiated, normothermic neonates are likely inappropriate. 6 For example, when standard gentamicin doses of 4-5 mg/kg every 24 hours were given to neonates with HIE receiving hypothermia, potentially toxic trough concentrations frequently occurred. 7, 33 In contrast, a customized every-36-hour dosing strategy that was developed based on an in-depth quantitative pharmacokinetic understanding of gentamicin in neonates with HIE receiving hypothermia, reliably achieved target drug exposures. 8 Similarly, a detailed examination of morphine pharmacokinetics in neonates with HIE receiving hypothermia is essential to help to understand optimal dosing strategies of morphine in this population.
In the final population pharmacokinetic model, the clearance of morphine and its glucuronide metabolites in neonates with HIE receiving hypothermia were significantly influenced by birthweight. Body size is a fundamental scalar of clearance in neonates, and weight has been previously described as a predictor of clearance in morphine and its metabolites in nonasphyxiated neonates. 12, 30 In these previous pharmacokinetic reports in neonates, the allometric exponent describing the relationship between weight and morphine clearance has been both estimated (k wt = 1.44) 12 and fixed (k wt = 0.75). 30 It is unknown what impact hypothermia may have on the theory-based relationship between size and clearance that has been used to justify fixing the exponent to 0.75. For example, hypothermia may impact clearance to a greater degree in lower-weight children than in higher-weight children. Therefore, in the current population pharmacokinetic model, the exponent was estimated and found to be 1.23.
After incorporating weight, the addition of a maturation function on morphine clearance using gestational age did not improve the model. Our study was limited by the narrow range of GA studied, which is inherent to the criterion used to qualify for hypothermia therapy (GA ࣙ 36 weeks) in neonates with HIE based on the original randomized, controlled trials. Therefore, our study likely had low power to find a developmental age effect on clearance. However, the lack of impact of developmental age on morphine clearance was also found in a larger population of nonasphyxiated neonates when the allometric weight exponent was estimated as in the current study. 12 Extrapolation of our pharmacokinetic model to neonates outside the range of GA and birthweight studied is not recommended.
Biomarkers of injury to organs important in drug elimination such as the liver and kidney may be helpful in identifying neonates with altered drug clearance. For example, we examined whether neonates with an elevated alanine aminotransferase (ALT) had reduced clearance of morphine, which is metabolized by UGT2B7 in the liver. A significant impact of ALT on morphine clearance was not found. In contrast, serum creatinine as a measure of renal function was a significant predictor of the clearance of both metabolites, which are eliminated almost exclusively via the kidney. The ability to characterize the impact of serum creatinine on metabolite clearance but not the impact of ALT on morphine clearance in our study is likely multifactorial. Serum creatinine is a specific biomarker of kidney function, whereas ALT indicates only hepatocyte injury and not function directly. In addition, although serum creatinine during the first days of life can be confounded by placental transfer, in neonates with HIE serum creatinine is frequently elevated beyond what would be expected from placental transfer in pregnant women (serum creatinine reference range, 0.4-0.9 mg/dL). 3, 4, 34, 35 In our current study, 9 neonates (45%) had a serum creatinine ࣙ 1.2 mg/dL. Therefore, when serum creatinine is elevated beyond what is expected from placental transfer, it may provide predictive information of underlying poor kidney function in neonates even during the first days of life. Serum creatinine was similarly shown to be predictive of gentamicin pharmacokinetics (a renally eliminated drug) in neonates with HIE receiving hypothermia. 7 Conversely, few neonates in our study had an elevated ALT (3 neonates had ALT ࣙ 100 U/L; only 1 neonate had ALT ࣙ500 U/L), and there was likely low power to uncover an effect of ALT on morphine clearance in our study. Consideration of liver injury may still be helpful in understanding morphine pharmacokinetics in neonate with HIE receiving hypothermia. For example, the lowest morphine clearance (scaled for weight) in our study population was observed in a neonate with the greatest liver injury (ALT >500 U/L). This neonate also had other clinical surrogates indicating multiorgan failure and likely altered physiology including mechanical ventilation need, inotropic support, pulmonary hypertension, and low urine output.
The independent effect of hypothermia on the pharmacokinetics of morphine was not able to be directly examined in the current study because all neonates received hypothermia. Because hypothermia is now firmly established as standard of care in neonates with HIE, similar limitations will face all future pharmacokinetic studies in this population. 36 Analyses applied to investigate the effect of hypothermia have included comparing a drug's pharmacokinetics in the same group of neonates with HIE during hypothermia (first 72 hours of life) versus after the neonate is rewarmed and normothermic (after 72 hours of life). 37 However, neonates with HIE have changing physiology over the first days of life independent of hypothermia. For example, because of organ maturation, drug clearance will increase during the first week of life. 38 In addition, hypoxic injury to the liver and kidney will also recover concurrently during this same period. Therefore, isolating the independent effect of hypothermia will be challenging and will require large, robust, and longitudinal data that provide enough power to model for the independent effect of maturation, organ dysfunction, and hypothermia.
Compared with reports in normothermic neonates without HIE, morphine clearance was reduced in neonates with HIE receiving hypothermia. The predicted morphine clearance in our study for a 3.5-kg neonate with HIE receiving hypothermia was 0.765 L/h, which is almost 50% lower than that reported for a normothermic neonate without HIE of 1.42 12 and 1.53 L/h. 30 Our results are in line with previous pharmacokinetic studies in neonates with HIE receiving hypothermia, which found reductions in drug clearance for gentamicin, 7 phenobarbital, 39 and topiramate. 40 The volume of distribution for a 3.5-kg neonate in our study (V 1 + V 2 = 8.0 L) was smaller than predicted based on a 2-compartment model in neonates without HIE (V 1 + V 2 = 12.7 L). 12 Decreases in volume during hypothermia have been reported for other drugs including for morphine in dogs. 41, 42 Because of the reduced clearance in neonates with HIE receiving hypothermia, typical recommended morphine sulfate doses for full-term neonates will be inappropriate. To develop optimized morphine sulfate dosing regimens for neonates with HIE receiving hypothermia, the final pharmacokinetic model was used to perform Monte Carlo simulations and examine different dosing strategies. A morphine sulfate loading dose of 50 μg/kg followed by a continuous infusion of 5 μg/kg/h was predicted to maximize target morphine drug concentrations of 10-40 ng/L. If intermittent dosing is used, a dose of 40 to 50 μg/kg every 6 hours was predicted.
A limitation to our exposure-matching approach is that morphine concentrations needed for analgesia in neonates with HIE receiving hypothermia are not established. It is also unclear how to account for the concentration of the active metabolite (M6G) in the therapeutic strategy because available pediatric pharmacodynamic data in the literature examined only morphine concentrations. However, the morphine exposure target used was extrapolated from previous studies in infants and neonates based on morphine concentrations shown to be effective and safe. [25] [26] [27] [28] The modeling and simulation approach applied provides an evidenced-based pharmacokinetic framework and starting point for the typical dose needs in neonates with HIE receiving hypothermia. In addition, the understanding gained can shed light on therapeutic considerations during morphine treatment in neonates with HIE receiving hypothermia. For example, accumulation of the active metabolite M6G is expected over the first 12-24 hours after starting an infusion, which may be clinically relevant, resulting in an increased (side) effect over time. Future pharmacodynamic studies of morphine in neonates will benefit by incorporation of both morphine and M6G concentrations in determining exposure-response. Lastly, because of the large variability in pharmacokinetics between neonates with HIE receiving hypothermia, further individualization in the therapeutic strategy for a given neonate will be necessary.
Performing clinical pharmacokinetic trials in critically ill neonatal populations is challenging because of limitations in clinical trial infrastructure, low consent rates, and restrictions in blood-sampling volumes. 43 The current study was facilitated by enrolling from 2 centralized, multidisciplinary neonatal neurocritical care units that emphasize continued practice improvement through evidenced-based clinical research. 44 We also were able to utilize microvolume pharmacokinetic sampling using DBS to minimize blood volume requirements. 16 Morphine concentrations in blood and plasma are known to be equivalent and allowed direct comparison of our study results with previous studies that measured drug concentrations in plasma. 45, 46 Last, our study design took advantage of medication administered as standard of care. Taken together, our study was completed in <12 months, and our consent rate approached more than 95%. The current study design may serve as a model for future drug trials in critically ill neonates.
Conclusions
In neonates with HIE receiving hypothermia, morphine clearance is markedly decreased compared with previous studies in full-term normothermic newborns without HIE. To avoid excessive accumulation of morphine, dosing strategies customized for this vulnerable population are needed. A continuous infusion of 5 μg/kg/h is predicted to optimize achievement of target concentrations associated with analgesia. For intermittent dosing, a dose of 40 to 50 μg/kg every 6 hours is predicted to be needed. Because of large variation between neonates with HIE in pharmacokinetics and pathophysiology, further individualization of the therapeutic strategy based on clinical considerations will be required.
